Compliance and Persistence with Osteoporosis Medications

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition

Volumn , Issue , 2013, Pages 448-454

  Gold, Deborah T ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Medication possession ratio (MPR); Osteoporosis medications

Indexed keywords

EID: 84893755426     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118453926.ch54     Document Type: Chapter

References (40)

1. Cramer JA, Lynch NO, Gaudin AF, Walker M, Cowell W. 2006. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France. Clin Ther 28 (10): 1686-94.
2. Huybrechts KF, Ishak KJ, Caro JJ. 2006. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38 (6): 922-8.
3. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. 2005. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48 (3): 271-87.
4. Silverman SL, Schousboe JT, Gold DT. 2011. Oral bisphosphonate compliance and persistence: A matter of choice? Osteoporos Int 22 (1): 21-6.
5. Hill MN, Miller NH, Degeest S, American Society of Hypertension Writing Group, Materson BJ, Black HR, Izzo JL Jr, Oparil S, Weber MA. 2011. Adherence and persistence with taking medication to control high blood pressure. J Amer Soc Hypertens 5 (1): 56-63.
6. Vawter L, Tong X, Gemilyan M, Yoon PW. 2008. Barriers to antihypertensive medication adherence among adults-United States, 2005. J Clin Hypertens 10 (12): 922-9.
7. Huser MA, Evans TS, Berger V. 2005. Medication adherence trends with statins. Adv Ther 22 (2): 163-71.
8. Rubin RR. 2005. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Amer J Med 118 Suppl 5A: 27S-34S.
9. Kulkarni KS, Balkrishnan R, Anderson RT, Edin HM, Kirsch J, Stacy MA. 2008. Medication adherence and associated outcomes in Medicare health maintenance organization-enrolled older adults with Parkinson's disease. Move Disord 23 (3): 359-365.
10. World Health Organization. 2003. Adherence to Long-Term Therapies: Evidence for Action. Geneva: World Health Organization.
11. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK. 2008. Medication compliance and persistence: Terminology and definitions. Value Health 11 (1): 44-7.
12. Badamgarav E, Fitzpatrick LA. 2006. A new look at osteoporosis outcomes: The influence of treatment, compliance, persistence, and adherence. Mayo Clin Proc 81 (8): 1009-12.
13. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S. 2006. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81 (8): 1013-22.
14. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. 2004. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15 (12): 1003-8.
15. Patrick AR, Brookhart MA, Losina E, Schousboe JT, Cadarette SM, Mogun H, Solomon DH. 2010. The complex relation between bisphosphonate adherence and fracture reduction. J Clin Endocrinol Metab 95 (7): 3251-9.
16. Papaioannou A, Ioannidis G, Adachi JD, Sebaldt RJ, Ferko N, Puglia M, Brown J, Tenenhouse A, Olszynski WP, Boulos P, Hanley DA, Josse R, Murray TM, Petrie A, Goldsmith CH. 2003. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14 (10): 808-13.
17. Ringe JD, Christodoulakos GE, Mellstrom D, Petto H, Nickelsen T, Marin F, Pavo I. 2007. Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women. Curr Med Res Opin 23 (11): 2677-87.
18. Farmer KC. 1999. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 21 (6): 1074-90.
19. Blandford L, Dans PE, Ober JD, Wheelock C. 1999. Analyzing variations in medication compliance related to individual drug, drug class, and prescribing physician. J Managed Care Pharm 5 (1): 47-51.
20. Silverman S. 2006. Adherence to medications for the treatment of osteoporosis. Rheum Dis Clin North Am 32 (4): 721-31.
21. Doshi JA, Zuckerman IH, Picot SJ, Wright JT Jr, Hill-Westmoreland EE. 2003. Antihypertensive use and adherence and blood pressure stress response among black caregivers and non-caregivers. Appl Nurs Res 16 (4): 266-77.
22. Boston Consulting Group. Analysis: Harris interactive 10,000 patient survey 2002. Available from: http://www. bcg.com/documents/file14265.pdf. Accessed: October 28, 2011.
23. Donovan JL, Blake DR. 1992. Patient non-compliance: Deviance or reasoned decision-making? Soc Sci Med 34 (5): 507-13.
24. Lowry KP, Dudley TK, Oddone EZ, Bosworth HB. 2005. Intentional and unintentional nonadherence to antihypertensive medication. Ann Pharmacother 39 (7-8): 1198-203.
25. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. 1985. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 313 (17): 1044-9.
26. Coronary Drug Project Research Group. 1980. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med 303 (18): 1038-41.
27. Cadarette SM, Solomon DH, Katz JN, Patrick AR, Brookhart MA. 2011. Adherence to osteoporosis drugs and fracture prevention: No evidence of healthy adherer bias in a frail cohort of seniors. Osteoporos Int 22 (3): 943-54.
28. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ. 2007. Systematic review and meta-analysis of realworld adherence to drug therapy for osteoporosis. Mayo Clin Proc 82 (12): 1493-501.
29. Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL. 2009. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122 (2 Suppl): S3-13.
30. Curtis JR, Delzell E, Chen L, Black D, Ensrud K, Judd S, Safford MM, Schwartz AV, Bauer DC. 2011. The relationship between bisphosphonate adherence and fracture: Is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. J Bone Miner Res 26 (4): 683-8.
31. Silverman SL, Gold DT. 2011. Healthy users, healthy adherers, and healthy behaviors? J Bone Miner Res 26 (4): 681-2.
32. Lindsay R. 1987. Estrogen therapy in the prevention and management of osteoporosis. Am J Obstet Gynecol 156 (5): 1347-51.
33. Riggs BL. 1979. Postmenopausal and senile osteoporosis: Current concepts of etiology and treatment. Endocrinol Jpn 26 (Suppl): 31-41.
34. Scoville EA, Ponce de Leon Lovaton P, Shah ND, Pencille LJ, Montori VM. 2011. Why do women reject bisphosphonates for osteoporosis? A videographic study. PLoS ONE 6 (4): e18468.
35. Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T. 2012. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 23 (1): 223-31.
36. Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V, Masanauskaite D. 2005. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: The Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21 (12): 1895-903.
37. Gold DT, SafiW, Trinh H. 2006. Patient preference and adherence: Comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 22 (12): 2383-91.
38. Kendler DL, Bessette L, Hill CD, Gold DT, Horne R, Varon SF, Borenstein J, Wang H, Man HS, Wagman RB, Siddhanti S, Macarios D, Bone HG. 2010. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int 21 (5): 837-46.
39. Arden NK, Earl S, Fisher DJ, Cooper C, Carruthers S, Goater M. 2006. Persistence with teriparatide in patients with osteoporosis: The UK experience. Osteoporos Int 17 (11): 1626-9.
40. Briot K, Ravaud P, Dargent-Molina P, Zylberman M, Liu-Leage S, Roux C. 2009. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: The French experience. Osteoporos Int 20 (4): 625-30.